Cavan S Reilly
Overview
Explore the profile of Cavan S Reilly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2073
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Enns E, Reilly C, Horvath K, Baker-James K, Henry K
AIDS Behav
. 2019 Mar;
23(9):2532-2541.
PMID: 30852729
Consistent engagement in care is associated with positive health outcomes among people living with HIV (PLWH). However, traditional retention measures ignore the evolving dynamics of engagement in care. To understand...
12.
Pragman A, Lyu T, Baller J, Gould T, Kelly R, Reilly C, et al.
Microbiome
. 2018 Jan;
6(1):7.
PMID: 29316977
Background: Oral taxa are often found in the chronic obstructive pulmonary disease (COPD) lung microbiota, but it is not clear if this is due to a physiologic process such as...
13.
Laguna T, Williams C, Nunez M, Welchlin-Bradford C, Moen C, Reilly C, et al.
Respir Res
. 2018 Jan;
19(1):6.
PMID: 29310632
Background: There are urgent needs for clinically relevant biomarkers to identify children with cystic fibrosis (CF) at risk for more progressive lung disease and to serve as outcome measures for...
14.
Enns E, Reilly C, Virnig B, Baker K, Vogenthaler N, Henry K
AIDS Patient Care STDS
. 2016 Sep;
30(9):409-15.
PMID: 27610462
Retention in care is essential to the health of people living with HIV and also for their communities. We sought to quantify the value of integrating HIV surveillance data with...
15.
Rawson J, Roth M, Xie J, Daly M, Clouser C, Landman S, et al.
Bioorg Med Chem
. 2016 Apr;
24(11):2410-2422.
PMID: 27117260
Although many compounds have been approved for the treatment of human immunodeficiency type-1 (HIV-1) infection, additional anti-HIV-1 drugs (particularly those belonging to new drug classes) are still needed due to...
16.
Rawson J, Daly M, Xie J, Clouser C, Landman S, Reilly C, et al.
Antimicrob Agents Chemother
. 2016 Feb;
60(4):2318-25.
PMID: 26833151
5-Azacytidine (5-aza-C) is a ribonucleoside analog that induces the lethal mutagenesis of human immunodeficiency virus type 1 (HIV-1) by causing predominantly G-to-C transversions during reverse transcription. 5-Aza-C could potentially act...
17.
Rudney J, Jagtap P, Reilly C, Chen R, Markowski T, Higgins L, et al.
Microbiome
. 2015 Dec;
3:69.
PMID: 26684897
Background: The etiology of dental caries is multifactorial, but frequent consumption of free sugars, notably sucrose, appears to be a major factor driving the supragingival microbiota in the direction of...
18.
Rawson J, Landman S, Reilly C, Bonnac L, Patterson S, Mansky L
Antimicrob Agents Chemother
. 2015 Aug;
59(11):6834-43.
PMID: 26282416
Decitabine has previously been shown to induce lethal mutagenesis of human immunodeficiency virus type 1 (HIV-1). However, the factors that determine the susceptibilities of individual sequence positions in HIV-1 to...
19.
Rawson J, Landman S, Reilly C, Mansky L
Retrovirology
. 2015 Jul;
12:60.
PMID: 26160407
Background: Human immunodeficiency virus type 2 (HIV-2) is often distinguished clinically by lower viral loads, reduced transmissibility, and longer asymptomatic periods than for human immunodeficiency virus type 1 (HIV-1). Differences...
20.
Laguna T, Reilly C, Williams C, Welchlin C, Wendt C
Pediatr Pulmonol
. 2015 Jun;
50(9):869-77.
PMID: 26115542
Background: Cystic fibrosis (CF) lung disease is characterized by infection, inflammation, lung function decline, and intermittent pulmonary exacerbations. However, the link between pulmonary exacerbation and lung disease progression remains unclear....